Andere Sprachen Edgewise Therapeutics, Inc.

Aktien

A2QRZ8

US28036F1057

EWTX

Realtime-Estimate Cboe BZX Andere Börsenplätze 15:43:39 16.04.2024			% 5 Tage	% 1. Jan.
16 ^USD	-2,91 %		-2,37 %	+50,64 %

15.04.	Edgewise Therapeutics, Inc. gibt positive Zwei-Jahres-Topline-Ergebnisse der offenen Arch-Studie mit Sevasemten (EDG-5506) bei Erwachsenen mit Becker-Muskeldystrophie (Becker) bekannt	CI
28.03.	Edgewise Therapeutics kündigt Podiumspräsentation auf der wissenschaftlichen Jahrestagung 2024 des American College of Cardiology an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Mixed Premarket Tuesday	15:21
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy	13:39
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	15.04.
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)	15.04.
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	15.04.
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28.03.
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28.03.
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024	27.03.
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024	05.03.
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference	28.02.
Edgewise Therapeutics Full Year 2023 Net Loss Widens	22.02.
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22.02.
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.02.
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22.02.
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	14.02.
Edgewise Therapeutics Drug Candidate to Treat Duchenne Gets FDA's Fast Track Designation	13.02.
Edgewise Shares Rise Premarket on FDA Fast-Track Designation	13.02.
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)	13.02.
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	13.02.
Edgewise Therapeutics Insider Sold Shares Worth $596,805, According to a Recent SEC Filing	09.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Edgewise Therapeutics, Inc.

Aktien

A2QRZ8

US28036F1057

EWTX

Andere Sprachen

Filter